Red Queen Bio
AI biosecurity company building scalable defenses against AI-enabled biological threats. Public Benefit Corporation backed by OpenAI.
Developing safety practices - core foundations in place with room for improvement.
Security Assessment
Security-relevant indicators for vendor evaluation
Dimension Breakdown
Social Impact & Safety Profile
StrongRed Queen Bio's core mission is preventing AI-enabled biological threats, one of the most consequential social impact areas in AI safety. Their biodefense work directly addresses catastrophic risk scenarios. The company's focus on biosafety represents active harm mitigation in a critical domain, though formal social impact reporting is still developing.
AI×Bio is the dual-use category of greatest concern to the AI safety community. The same AI capabilities that accelerate drug discovery and medical research could theoretically be misused for pathogen design or biological weapon development.
Civilizational Risk Awareness
For a company operating at the AI×Bio intersection, the bar for catastrophic risk awareness should be higher than for other AI companies. The current level of public communication on this topic is insufficient for the risk profile.
Responsible Scaling Policy
No published RSP or equivalent. For an AI×Bio company, the equivalent would be a biosafety scaling policy governing how AI capabilities are gated against biosecurity risk thresholds.
Mission Drift Protection
- ○No PBC status
- ○No structural governance mechanisms
- ○No published biosafety governance framework
- ○No independent biosafety advisory board
Vulnerability Disclosure
No CVD programme. For an AI×Bio company, relevant vulnerabilities include: unintended generation of dangerous biological information, insufficient access controls on dual-use capabilities.
Safety Reporting
No safety reporting. For an AI×Bio company, regular safety reporting is especially important given the dual-use risk profile.
Dual-Use Risk
Significant dual-use risk. The absence of published biosecurity governance and dual-use assessment is the most important gap. Even well-intentioned companies at this intersection need structured, transparent governance. The industry lacks standards, but leadership companies should set the standard rather than wait for it.
Mitigation details
Need a detailed report for Red Queen Bio?
Subscribe to express interest in indicator-level evidence, peer benchmarking, and regulatory gap analysis - or reach out to request a full company overview brief.